Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.

ABSTRACT:

Background

It is important to monitor the association between menopausal hormone therapy (HT) use and breast cancer (BC) risk with contemporary estimates, and specifically focus on HT types and new drugs.

Methods

We estimated hazard ratios (HR) of BC risk according to HT type, administration route and individual drugs, overall and stratified by body mass index (BMI), molecular subtype and detection mode, with non-HT use as reference.

Results

We included 1,275,783 women, 45+ years, followed from 2004, for a median of 12.7 years. Oral oestrogen combined with daily progestin was associated with the highest risk of BC (HR 2.42, 95% confidence interval (CI) 2.31-2.54), with drug-specific HRs ranging from Cliovelle®: 1.63 (95% CI 1.35-1.96) to Kliogest®: 2.67 (2.37-3.00). V

SUBMITTER: Stoer NC 

PROVIDER: S-EPMC11231299 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature